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E xperimental data obtained through new high-throughput techniques and big data analysis have provided a better 
understanding of the mechanisms leading to the onset of auto-
immune disease, as well as the perpetuation of chronic inflam-
mation. While infections and autoimmunity have been linked 
for decades, the role of microorganisms and parasites has not 
been definitively established since infections may act as triggers 
of autoimmune diseases in predisposed subjects [1-4] or, as pro-
posed by the hygiene hypothesis, as protective agents towards 
the development of autoimmunity [5,6]. In recent decades 
the prevalence of autoimmunity has increased dramatically 
in Western countries, likely secondary to the growing aware-
ness among physicians and an easier access to diagnosis (as in 
the case of disease-specific serum autoantibodies [7]), but the 
decrease in infection rates could be responsible for the rapidly 
increasing burden of chronic inflammatory conditions [8]. 
Beyond geoepidemiology, the evidence in support of 
the infection-autoimmunity link is seen in subjects living 
in a region of Northern Europe shared between Russia and 
Finland, where people living in the Finnish part of the region 
manifested a higher rate of autoimmune disease, while the 
Russian population was more likely to have infections [9,10]. 
In general terms, the link has been considered a one-way street, 
with infectious agents triggering or perpetuating inflammation, 
until this dogma was shattered by the enormous amount of data 
in support of the modulatory effect of the microbiota [11-13]. 
Indeed, bacteria and parasites could act as immunomodulatory 
organisms and shift the immune response towards regulatory 
pathways [9]. Based on these findings, manipulation of the 
microorganisms and parasites that live in conjunction with cells 
on our skin and mucosa represents an area of growing inter-
est for many autoimmune diseases [14]. Helminths represent 
a fascinating area of research since, different from the majority 
of infectious agents, their purpose is to coexist and thrive with 
rather than kill the host. Therefore, they try to induce a tolerable 
scenario [15]. Several mechanisms are involved in this immune 
response, such as switching the immune reaction from Th1 to 
Th2, changing the secreted cytokines toward interleukin (IL)-10, 
increasing the amount of T regulatory cells, and more recently 
identifying the suppression of Th17 and release of biologically 
active excretory-secretory antigens that directly modulate host 
immune function [6,9,15]. Thus, helminthic supplementation is 
gaining much interest as a therapeutic tool, and researchers are 
enthusiastic to explore its role in autoimmunity, as suggested by 
the increasing number of studies [16]. 
The road of helminthic therapies began in the 1990s, when 
these organisms were used as therapeutic agents in experimen-
tal models and clinical studies of several immune-mediated 
conditions, including inflammatory bowel disease, multiple 
sclerosis, rheumatoid arthritis, type 1 diabetes, celiac disease, 
Graves’ disease and psoriasis [15]. Various species of helminths 
and different approaches were evaluated, including colonization 
by helminth larvae, oral administration of helminth ova, and 
the use of helminth-derived antigens. So far, in small clinical 
trials the ova treatments appear to be successful and safe for 
patients with inflammatory bowel disease and multiple sclerosis 
[17-19]. 
However, the benefit was not shown to be specific to single 
helminth species, and special interest has grown around the 
immunomodulatory molecules released by the parasites into 
the host environment [20], mainly phosphorylcholine-moiety 
glycoproteins [21]. Phosphorylcholine can be found in a wide 
range of bacterial infections, like Streptococcus pneumoniae and 
Haemophilus influenzae, and it is secreted by filarial nematodes. 
Phosphorylcholine mediates the regulation of adherence 
to cells, encountering the host’s innate immune system and 
adaptive immune system, and in the regulation of cell growth.
Currently, as new methods are emerging and technology has 
improved, synthetic small molecules are available. Researchers 
developed the synthetic molecule tuftsin-phosphorylcholine 
(TPC) consisting of phosphorylcholine and tuftsin, considered 
to be a “natural adjuvant,” already used in vaccines, that stimu- 
lates phagocytic activity, increases migration and activation of 
macrophages, and enhances chemotaxis of monocytes [22,23]. 
KEY WORDS:
140 
The 4Th Israel-ITaly MeeTIng IMAJ • VOL 18 • march-aPrIL 2016
This small molecule has been shown in a mouse model of colitis 
to reduce its severity in all observed manifestations, including 
weight loss, intestinal bleeding, colonic length, and histologi-
cal damage, resulting in improved survival [24]. Moreover, in 
genetically lupus-prone mice it ameliorated various manifes-
tations of the disease, especially kidney disease, with a reduc-
tion in glomerular immune-complex deposition, less severe 
inflammatory response and reduced kidney damage, fol-
lowed by delayed onset of proteinuria and improved survival. 
Interestingly, serum anti-dsDNA antibody titers did not vary 
with treatment [25]. Finally, TPC has been evaluated also in 
a collagen-induced arthritis mouse model, showing promising 
results in both subcutaneous and orally treated groups: TPC-
treated mice had a significantly lower arthritis score, reduced 
histological modifications, decreased titers of circulating col-
lagen II antibodies, reduced pro-inflammatory cytokines and 
increased anti-inflammatory cytokine expression, as well as 
expansion of Treg and Breg cells [26]. Interestingly, tuftsin or 
phosphorylcholine by themselves had a moderate effect on 
disease progression. It has been hypothesized that the clinical 
efficacy of TPC may be attributed to its potential to reduce pro-
inflammatory cytokine production, such as interferon-gamma 
and IL-17, and to significantly increase the anti-inflammatory 
cytokine profile, such as transforming growth factor-beta and 
IL-10 [26]. Advantages of TPC and other small molecules 
include the possibility of both subcutaneous and oral adminis-
tration. It could serve as treatment and prophylaxis for diverse 
autoimmune conditions, especially at early stages with minimal 
adverse effects. 
In conclusion, there is an urgent need for new therapies 
for autoimmune diseases that can modify disease progression 
with an optimal safety profile, especially in patients who have 
high unmet medical needs, like tumor necrosis factor-alpha 
inhibitor refractory rheumatoid arthritis or psoriasis, multiple 
sclerosis or severe inflammatory bowel disease, or orphan dis-
eases for which no therapies exist. Helminth-derived immu-
nomodulatory therapies could serve as potential treatment for 
these patients, and we await the human data that are needed to 
ensure a good safety profile of such approaches.
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“We make a living by what we get, but we make a life by what we give”
Winston Churchill
